Effects of chronic administration of alogliptin on the development of diabetes and β ‐cell function in high fat diet/streptozotocin diabetic mice
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Aim: Alogliptin is a potent and highly selective dipeptidyl peptidase‐4 (DPP‐4) inhibitor. The aim of this study was to determine its effects on glucose control and pancreas islet function and to identify the underlying molecular mechanisms after chronic administration, in a non‐genetic mouse model of type 2 diabetes. Methods: Alogliptin (5, 15 and 45 mg/kg) was orally administered to high fat diet/streptozotocin (HFD/STZ) diabetic mice daily for 10 weeks. Postprandial and 6‐h fasting blood glucose levels, blood A1C level, oral glucose tolerance and pancreas insulin content were measured during or after the treatment period. Alogliptin plasma concentration was determined by an LC/MS/MS method. Islet morphology and architectural changes were evaluated with immunohistochemical analysis. Islet endocrine secretion ability was assessed by measuring insulin release from isolated islets which were challenged with 16 mM glucose and 30 mM potassium chloride, respectively. Gene expression profiles of the pancreas were analysed using the mouse diabetes RT 2 Profiler PCR array which contains 84 genes related to the onset, development and progression of diabetes. Results: Alogliptin showed dose‐dependent reduction of postprandial and fasting blood glucose levels and blood A1C levels. Glucose clearance ability and pancreas insulin content were both increased. Alogliptin significantly restored the β ‐cell mass and islet morphology, thus preserving islet function of insulin secretion. Expression of 10 genes including Ins1 was significantly changed in the pancreas of diabetic mice. Chronic alogliptin treatment completely or partially reversed the abnormalities in gene expression. Conclusions: Chronic treatment of alogliptin improved glucose control and facilitated restoration of islet architecture and function in HFD/STZ diabetic mice. The gene expression profiles suggest that the underlying molecular mechanisms of β ‐cell protection by alogliptin may involve alleviating endoplasmic reticulum burden and mitochondria oxidative stress, increasing β ‐cell differentiation and proliferation, enhancing islet architecture remodelling and preserving islet function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“As GLP-1 and GIP from the gastrointestinal tract link nutrient absorption and insulin secretion from β-cells [11], partial recovery of abnormal glucose clearance after alogliptin treatment indicates an offset of impaired incretin response and β-cell functional preservation [33].”
BackgroundReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“In T2DM patients, the incretin effects were found to be impaired [18].”
BackgroundXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Lambeir, A.-M., Durinx, C., Scharpé, S., & De Meester, I. (2003) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/713609354 · Cited by 955
Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917 · cited 1×
“It is characterized by impaired insulin responsiveness and anatomical abnormalities of the pancreatic islets during the course of the disease [1,2].”
BackgroundMetabolic and molecular basis of insulin resistance
Bajaj, M., & DeFronzo, R. A. (2003) · Journal of Nuclear Cardiology · doi:10.1016/s1071-3581(03)00520-8 · Cited by 131
Emerging roles for the TGFβ family in pancreatic β-cell homeostasis
Brown, M. L., & Schneyer, A. L. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.02.008 · Cited by 63 · cited 10×
“As a member of the transforming growth factor β family and encoded by Tgfb1, TGFβ1 medicates glucose homeostasis in the extracellular matrix and regulates β-cell function and proliferation [42].”
BackgroundInfluentialMcGinn, S., Poronnik, P., King, M., Gallery, E. D. M., & Pollock, C. A. (2003) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00466.2002 · Cited by 63
Cited by
Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls
Drucker, D. J. (2013) · Diabetes · doi:10.2337/db13-0822 · Cited by 272
Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
Golightly, L. K., Drayna, C. C., & McDermott, M. T. (2012) · Clinical Pharmacokinetics · doi:10.1007/bf03261927 · Cited by 158
Ta, N. N., Schuyler, C. A., Li, Y., Lopes-Virella, M. F., & Huang, Y. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31821e5626 · Cited by 156
Self-citationRameshrad, M., Razavi, B. M., Ferns, G. A. A., & Hosseinzadeh, H. (2019) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-019-00238-7 · Cited by 34
Metadata
- Authors
- Zhang, X., Wang, Z., Huang, Y., & Wang, J.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2011-02-23
- Volume
- 13
- Issue
- 4
- Pages
- 337-347
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2005404676
- Cited by
- 57
- References
- 9
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of chronic administration of alogliptin on the development of diabetes and β ‐cell function in high fat diet/streptozotocin diabetic mice. https://app.cochat.ai/papers/10.1111/j.1463-1326.2010.01354.x
- The paper
- Zhang, X., Wang, Z., Huang, Y., & Wang, J. (2011). Effects of chronic administration of alogliptin on the development of diabetes and β ‐cell function in high fat diet/streptozotocin diabetic mice. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2010.01354.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.